Peptide Evidence Index

Tirzepatide

Evidence last reviewed: September 2026

Quick answers

What is it?: Tirzepatide is a synthetic peptide that activates two gut-hormone receptors at once — GIP and GLP-1 — approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea.
Why are people interested in it?: In head-to-head trials it produced greater weight loss and glucose-lowering than the leading single-receptor GLP-1 drug, semaglutide.
What has actually been studied?: Large, industry-run, placebo- and comparator-controlled randomized trials in adults with type 2 diabetes or obesity, running 40 to 88 weeks.
How strong is the evidence?: Strong and consistent — FDA-approved for three indications — but built almost entirely on trials designed and run by the drug's manufacturer in defined populations.
What don't we know yet?: What happens with more than two years of use, and how the drug performs in people with recent serious psychiatric history, since pivotal trials excluded them.
Where can I read the original research?: Sources at the bottom of this page: SURMOUNT-1 (Jastreboff et al., NEJM 2022) and SURPASS-2 (Frías et al., NEJM 2021).

Plain-English overview

Tirzepatide is a synthetic 39-amino-acid peptide that activates two different gut-hormone receptors at once, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1, rather than the single GLP-1 receptor targeted by earlier drugs like semaglutide and liraglutide. A fatty-acid chain lets it bind albumin in the blood, extending its half-life to about five days and allowing once-weekly injection. It is FDA-approved as Mounjaro for type 2 diabetes, as Zepbound for chronic weight management, and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. In placebo-controlled and head-to-head trials it has produced larger average weight loss and glucose-lowering than semaglutide, the single-receptor GLP-1 drug it has been tested against directly. The evidence base is large — 277 registered human trials — but comes almost entirely from trials designed and run by its manufacturer, Eli Lilly, in specific, protocol-defined populations.

What researchers are studying it for

Type 2 diabetes (glycemic control)
Chronic weight management in adults with overweight or obesity
Moderate-to-severe obstructive sleep apnea in adults with obesity

Current evidence level

Randomized trials

Regulatory status: Approved medicine. Evidence strength and approval are scored separately; approval is a regulatory decision about a specific use, not a measure of how much research exists.

Human research

SURMOUNT-1 (Jastreboff et al., NEJM 2022) randomized 2,539 adults with obesity or overweight and no diabetes to weekly tirzepatide 5, 10, or 15 mg, or placebo, for 72 weeks; at the highest dose, mean weight loss was 20.9% versus 3.1% with placebo. SURPASS-2 (Frías et al., NEJM 2021) compared tirzepatide directly against semaglutide 1 mg in 1,879 adults with type 2 diabetes on background metformin over 40 weeks; all three tirzepatide doses produced significantly greater reductions in both HbA1c and body weight than semaglutide. SURMOUNT-2 (Garvey et al., Lancet 2023) tested tirzepatide specifically in adults who have both obesity and type 2 diabetes — a population that typically loses less weight on incretin drugs — and again found significant weight loss and glycemic improvement versus placebo over 72 weeks. SURPASS-3 (Ludvik et al., Lancet 2021) compared tirzepatide against once-daily insulin degludec, added to metformin with or without an SGLT2 inhibitor, and found greater HbA1c reduction and weight loss with tirzepatide than with insulin. SURMOUNT-4 (Aronne et al., JAMA 2024) put 783 adults through a 36-week open-label lead-in on tirzepatide, during which they lost a mean 20.9% of body weight, then randomized 670 of them to continue tirzepatide or switch to placebo for 52 more weeks; the placebo group regained 14.0% of body weight while the group that continued lost a further 5.5%. SURMOUNT-OSA (Malhotra et al., NEJM 2024), the trial behind the sleep-apnea indication, tested tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea and reported reduced breathing-interruption frequency during sleep compared with placebo. Across this program, doses were reached through a supervised weekly step-up schedule, not a flat starting dose.

Animal and preclinical research

Rodent studies found thyroid C-cell tumors with tirzepatide and related drugs in this class, which is why tirzepatide carries a boxed warning about medullary thyroid carcinoma risk and is contraindicated in people with a personal or family history of that cancer or of multiple endocrine neoplasia type 2. Whether the rodent finding translates into human risk has not been confirmed or ruled out. The source material reviewed here does not describe other preclinical studies in detail.

Major findings

SURMOUNT-1: mean 20.9% body-weight reduction over 72 weeks at the highest dose, versus 3.1% with placebo, in 2,539 adults with obesity/overweight without diabetes.
SURPASS-2: all three tirzepatide doses beat semaglutide 1 mg on both HbA1c and body weight in 1,879 adults with type 2 diabetes over 40 weeks.
SURMOUNT-2: significant weight loss and glycemic improvement in adults who have both obesity and type 2 diabetes, a harder-to-treat population.
SURPASS-3: greater HbA1c reduction and weight loss than once-daily insulin degludec.
SURMOUNT-4: continuing tirzepatide after a 36-week lead-in produced a further 5.5% weight loss, versus 14.0% regain on placebo — roughly a 19-percentage-point gap.
SURMOUNT-OSA: reduced sleep-apnea severity in adults with obesity, supporting the December 2024 FDA indication.
277 studies registered on ClinicalTrials.gov, with well over a hundred completed and posted.

What has not been established

Long-term safety and effectiveness beyond about two years; most trial windows run 40 to 88 weeks.
Whether the rodent thyroid C-cell tumor signal translates to human risk.
Effects in people with a recent serious psychiatric history or a lifetime suicide attempt — pivotal obesity trials excluded them by design.
Effects in people with a history of pancreatitis or medullary thyroid carcinoma/MEN2, since these groups were excluded from every pivotal trial.
Independent, non-industry-run replication at the scale of the pivotal program — nearly all trials cited were designed and funded by the manufacturer.

Important limitations

Nearly all pivotal evidence comes from trials designed, run, and funded by Eli Lilly, the drug's manufacturer.
Populations were narrowly defined by protocol, excluding pancreatitis history, thyroid cancer history, and recent significant psychiatric illness.
Longest published outcome windows are under two years; multi-decade safety is unknown.
Most of the 277 registered trials are dose-finding, pharmacokinetic, or comparator studies rather than independent replications of the pivotal endpoints.
Stopping the drug reverses most of its weight-loss effect, per SURMOUNT-4, so trial results describe a chronic-treatment effect, not a one-time change.

Regulatory status

Approved by the FDA as Mounjaro (subcutaneous injection) in May 2022 for type 2 diabetes; as Zepbound in November 2023 for chronic weight management in adults with obesity or overweight plus a weight-related condition; and with an added indication in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. Not on the World Anti-Doping Agency's Prohibited List.

Primary research sources

Jastreboff AM et al., SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity: NEJM 2022; PMID 35658024; ClinicalTrials.gov NCT04184622
Frías JP et al., SURPASS-2: Tirzepatide vs Semaglutide Once Weekly in Type 2 Diabetes: NEJM 2021; PMID 34170647; ClinicalTrials.gov NCT03987919
Aronne LJ et al., SURMOUNT-4: Continued Treatment vs Withdrawal for Maintenance of Weight Reduction: JAMA 2024; PMID 38078870; ClinicalTrials.gov NCT04660643
Garvey WT et al., SURMOUNT-2: Tirzepatide for Obesity in Type 2 Diabetes: Lancet 2023; PMID 37385275; ClinicalTrials.gov NCT04657003
Ludvik B et al., SURPASS-3: Tirzepatide vs Insulin Degludec in Type 2 Diabetes: Lancet 2021; PMID 34370970; ClinicalTrials.gov NCT03882970
Malhotra A et al., SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea and Obesity: NEJM 2024; PMID 38912654; ClinicalTrials.gov NCT05412381

Full evidence entry (complete data, registry records, dosing evidence)

Approved medicine

Approved by a major regulator for a specific use

At a glance

Also known as: Mounjaro, Zepbound
Class: Dual GIP/GLP-1 receptor agonist
Derived from: A synthetic 39-amino-acid peptide engineered to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor, carrying a fatty-acid chain that binds albumin to extend its half-life to about five days
Registered human trials: 277
…with published results: well over a hundred, including every pivotal trial cited below (counted on ClinicalTrials.gov this session)
Largest human trial: 2,539 adults with obesity or overweight, without diabetes (SURMOUNT-1, 2022) — the highest tirzepatide dose produced a mean 20.9% body-weight reduction over 72 weeks versus 3.1% with placebo
Studied for: type 2 diabetes (glycemic control), chronic weight management in overweight/obesity, moderate-to-severe obstructive sleep apnea in adults with obesity
Dosing evidence: Prescribed by a clinicianEvery studied dose followed a supervised weekly step-up schedule defined by the trial protocol and, in practice, by a prescriber following the FDA-approved label.
Regulatory status: Approved by the FDA as Mounjaro (subcutaneous injection) in May 2022 for type 2 diabetes; as Zepbound in November 2023 for chronic weight management in adults with obesity or overweight plus a weight-related condition; and with an added indication in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.
Anti-doping status: Not on the World Anti-Doping Agency's Prohibited List

What it is

Tirzepatide is a synthetic peptide that activates two different gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Older drugs in this class — semaglutide, liraglutide, dulaglutide — act on GLP-1 alone; tirzepatide's dual action is the basis for its marketing as a "twincretin." Like semaglutide, it carries a fatty-acid chain that binds albumin in the blood, giving it roughly a five-day half-life and allowing once-weekly dosing.

It is FDA-approved as Mounjaro for type 2 diabetes, as Zepbound for chronic weight management, and — since December 2024 — for moderate-to-severe obstructive sleep apnea in adults with obesity.

What the studies actually found

SURMOUNT-1 (Jastreboff et al., NEJM 2022; PubMed PMID 35658024, DOI) randomized 2,539 adults with obesity or overweight and no diabetes to weekly tirzepatide 5, 10, or 15 mg, or placebo, for 72 weeks. At the highest dose, mean weight loss was 20.9% versus 3.1% with placebo; on the two higher doses, roughly half to just over half of participants lost 20% or more of their body weight, versus 3% on placebo.

SURPASS-2 (Frías et al., NEJM 2021; PubMed PMID 34170647, DOI) compared tirzepatide directly against semaglutide: 1,879 adults with type 2 diabetes on background metformin were randomized to tirzepatide 5/10/15 mg or semaglutide 1 mg (the highest approved diabetes dose of semaglutide at the time) for 40 weeks. All three tirzepatide doses produced significantly greater reductions in both HbA1c and body weight than semaglutide.

What exists in humans

277 studies listing tirzepatide as an intervention are registered on ClinicalTrials.gov as of this session — a shorter but still substantial program, reflecting the drug's 2022 market entry. Well over a hundred are completed with posted results, including the SURPASS series in diabetes and the SURMOUNT series in obesity.

The pivotal obesity trials excluded people with a history of pancreatitis, a personal or family history of medullary thyroid carcinoma or MEN2, and — notably — anyone with a lifetime history of a suicide attempt or a significant active psychiatric disorder in the prior two years. That is a meaningful population boundary: the weight-loss evidence base was built in a group screened to exclude serious psychiatric history, which matters given ongoing public discussion about mood effects across this drug class.

What doses have been studied in humans

Every trial used a supervised titration, not a flat starting dose. In SURMOUNT-1, 2,539 adults without diabetes received weekly subcutaneous injections escalated over 20 weeks to a target of 5, 10, or 15 mg, continued to week 72; the coprimary endpoints were percent weight change and the proportion achieving at least 5% weight loss. In SURPASS-2, 1,879 adults with type 2 diabetes on background metformin were escalated over several weeks to the same three tirzepatide doses, compared against semaglutide 1 mg, over 40 weeks, with HbA1c change as the primary endpoint.

As with any prescription medicine, the specific starting dose, escalation pace, and target maintenance dose for an individual patient are set by a prescriber against the FDA-approved label for that patient's indication — informed by, but not identical to, any single trial's protocol. Nothing here describes what a reader should take.

What remains unknown

What happens after stopping. SURMOUNT-4 (Aronne et al., JAMA 2024; PMID 38078870, DOI) put 783 adults through a 36-week open-label lead-in on tirzepatide, during which they lost a mean 20.9% of body weight, then randomized 670 of them to continue tirzepatide or switch to placebo for 52 more weeks. The placebo group regained weight equal to 14.0% of body weight over that period, while the group that continued tirzepatide lost a further 5.5% — a difference of about 19 percentage points. As with semaglutide, this is treatment for a chronic condition, not a fixed course.
Longest published trial windows are under two years. Most safety data covers 72 to 88 weeks, not decades of use.
Thyroid C-cell tumors, flagged in rodent studies, carry the same boxed warning and unresolved human-risk question as GLP-1-only drugs.
Psychiatric effects are an active area of post-marketing surveillance; the pivotal trials, by design, excluded people with recent serious psychiatric history, so they cannot fully answer questions now being raised about that population.

Registry and study records

SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity: ClinicalTrials.gov NCT04184622 · n=2,539, main phase completed 2022 (trial fully completed 2024), results posted; Jastreboff et al., NEJM 2022
SURPASS-2: Tirzepatide vs Semaglutide Once Weekly in Type 2 Diabetes: ClinicalTrials.gov NCT03987919 · n=1,879, completed 2021, results posted; Frías et al., NEJM 2021
SURMOUNT-4: Continued Treatment vs Withdrawal for Maintenance of Weight Reduction: ClinicalTrials.gov NCT04660643 · n=783 enrolled (670 randomized after lead-in), completed 2023, results posted; Aronne et al., JAMA 2024

See the full Evidence Index →

Evidence last reviewed: September 2026. Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.